NAD+ (nicotinamide adenine dinucleotide) has generated significant interest in both clinical and consumer wellness contexts over the past decade. The interest is not unfounded — NAD+ plays a fundamental role in cellular energy metabolism and has been the subject of serious research. It has also attracted overclaiming that outpaces the evidence. What follows is an honest account of what NAD+ IV therapy does, what the evidence supports, and who is most likely to benefit.
What NAD+ is and why it matters
NAD+ is a coenzyme present in every cell of the body. It exists in two forms — NAD+ (oxidized) and NADH (reduced) — and cycles between them as it participates in energy production. Its primary roles:
Mitochondrial function. NAD+ is essential to the electron transport chain — the biochemical process by which mitochondria convert substrates (glucose, fatty acids, amino acids) into ATP (cellular energy). Without adequate NAD+, mitochondrial ATP production is impaired.
Sirtuin activation. Sirtuins are a class of proteins involved in DNA repair, gene expression, and stress response. They are NAD+-dependent. Declining NAD+ levels impair sirtuin function, which has downstream effects on cellular aging and metabolic regulation.
DNA repair. PARP enzymes, which detect and repair DNA strand breaks, consume NAD+ as a substrate. High oxidative stress environments (chronic inflammation, toxin exposure, aging) increase PARP activity and NAD+ consumption.
Why NAD+ declines with age
NAD+ levels decline progressively with age — by some estimates, halving between young adulthood and older age. The mechanisms include reduced biosynthesis from precursors, increased consumption by PARPs and sirtuins in response to aging-related DNA damage and inflammation, and reduced availability of dietary precursors. The result is a cellular environment that is less metabolically efficient and less capable of repair.
IV delivery versus oral supplementation
Oral NAD+ precursors — NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) — are bioavailable and produce measurable increases in cellular NAD+ levels in clinical trials. They are reasonable for maintenance and general wellness support.
IV NAD+ bypasses oral absorption entirely, delivering NAD+ directly into circulation. This produces a more immediate and pronounced effect on plasma NAD+ levels than oral supplementation. The clinical rationale for IV delivery in specific patients — those with significant fatigue, post-illness recovery, metabolic dysfunction, or demanding cognitive and physical requirements — is that the larger acute increase in NAD+ availability may produce more rapid and noticeable clinical effects than oral precursors.
NAD+ infusion starts with a clinical assessment.
All Revitalize IV therapies begin with a brief evaluation to confirm candidacy and select the right protocol for your goals.
View IV Hydration ServicesThe honest caveat: head-to-head clinical trials comparing IV NAD+ to oral NMN or NR on patient-centered outcomes (energy, fatigue, cognitive function) are limited. The mechanistic rationale is sound; the clinical comparative evidence remains incomplete.
What the evidence supports
Energy and fatigue. Multiple clinical reports and patient series support meaningful improvement in energy and reduction of fatigue following IV NAD+ infusion, particularly in patients with mitochondrial substrate depletion. This is the most consistently reported clinical effect.
Cognitive performance. Some patients report notable improvements in mental clarity and focus following infusion. The mechanism — improved neuronal energy availability and sirtuin activity — is plausible. Formal clinical trial evidence in non-disease populations is limited.
Addiction and withdrawal support. IV NAD+ has the strongest clinical evidence base in addiction medicine, where it has been used to reduce withdrawal symptoms and cravings. This specific indication has more structured clinical evidence behind it.
What the evidence does not support
Overclaiming about NAD+ IV therapy as a direct anti-aging treatment or longevity extension in humans is not currently supported by definitive clinical trial evidence. The mechanistic connection between NAD+ and aging pathways is well-established in animal models; human longevity outcome data is not yet available.
The infusion experience at Revitalize includes a clinical assessment prior to IV therapy to ensure appropriateness and to identify whether IV NAD+, a micronutrient formula, or a combination approach is most relevant. IV hydration therapy is adjunctive — it supports the clinical picture rather than replacing hormonal or metabolic optimization.
Who benefits most
Patients most likely to benefit from NAD+ IV therapy: those with significant fatigue that has not fully responded to hormonal correction, those in high cognitive or physical demand periods, those recovering from illness or significant physiological stress, and those with documented metabolic dysfunction where mitochondrial substrate support is clinically relevant.
For most patients, IV hydration therapy is a periodic complement to ongoing hormonal and metabolic care — not a primary intervention.
Medical disclaimer: This article is for educational purposes only and does not constitute medical advice. Individual clinical decisions should be made in consultation with a qualified healthcare provider following appropriate evaluation. References to specific treatments, dosing, or protocols are informational.
Travis spent 17+ years in high-acuity clinical medicine — emergency, cardiac ICU, and cath lab — before founding Revitalize. He is a Certified Platinum Biote hormone therapy provider, the published author of You're Not Broken — You're Unbalanced, and the founder of the Rebuild Metabolic Health Institute. His clinical writing reflects the same precision he brought to critical care: specific, honest, and built around what actually works.
